225 Shares in argenx SE (NASDAQ:ARGX) Bought by Belpointe Asset Management LLC

Belpointe Asset Management LLC bought a new stake in shares of argenx SE (NASDAQ:ARGX – Get Rating) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 225 shares of the company’s stock, valued at approximately $85,000.

Several other hedge funds have also bought and sold shares of ARGX. KB Financial Partners LLC lifted its position in shares of argenx by 112.5% during the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 45 shares in the last quarter. Guardian Wealth Advisors LLC bought a new position in shares of argenx in the third quarter worth approximately $31,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of argenx in the fourth quarter worth $37,000. Ronald Blue Trust Inc. raised its position in shares of argenx by 728.6% during the 4th quarter. Ronald Blue Trust Inc. now owns 116 shares of the company’s stock valued at $41,000 after purchasing an additional 102 shares during the period. Finally, Captrust Financial Advisors lifted its stake in shares of argenx by 116.7% during the 1st quarter. Captrust Financial Advisors now owns 143 shares of the company’s stock valued at $45,000 after buying an additional 77 shares in the last quarter. Institutional investors own 57.29% of the company’s stock.

argenx Trading Up 2.2 %

ARGX stock opened at $422.58 on Friday. The stock has a market cap of $23.53 billion, a PE ratio of -45.49 and a beta of 0.75. argenx SE has a 12 month low of $304.14 and a 12 month high of $422.58. The company has a 50-day moving average price of $382.23 and a 200 day moving average price of $377.79.

argenx (NASDAQ:ARGX – Get Rating) last posted its quarterly earnings results on Thursday, March 2nd. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($3.08) by $2.38. argenx had a negative net margin of 79.45% and a negative return on equity of 35.36%. The firm had revenue of $182.12 million during the quarter, compared to the consensus estimate of $177.11 million. Sell-side analysts forecast that argenx SE will post -6.33 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ARGX. Bank of America raised their price target on argenx from $444.00 to $446.00 in a report on Friday, May 5th. Citigroup started coverage on shares of argenx in a report on Tuesday, April 25th. They set a “buy” rating and a $450.00 price objective for the company. JMP Securities lowered their target price on shares of argenx from $448.00 to $445.00 in a report on Friday, May 5th. Piper Sandler raised their target price on shares of argenx from $465.00 to $475.00 and gave the company an “overweight” rating in a research note on Thursday, February 23rd. Finally, Cowen lifted their price target on shares of argenx from $441.00 to $458.00 and gave the company an “outperform” rating in a report on Wednesday, January 25th. One equities research analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $454.24.

argenx Company Profile

(Get Rating)

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.